ArticleJournal of global infectious diseases2010
Immunological perspectives of leishmaniasis.
Article in Journal of global infectious diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed.
- An Insight Into Systemic Immune Response inFrontiers in immunology · 2021Trial
- Evaluation of the Cutaneous Immunological Milieu Before and After Treatment With Meglumine Antimoniate in Dogs Naturally Affected by Leishmaniosis due to Leishmania infantum.Veterinary dermatology · 2026Article
- Circular RNAs: An Under-Recognized Part in Different Scenarios of Host-Parasite Interrelationships.Pathogens (Basel, Switzerland) · 2026Review
- Non-additive strong gene interactions cause striking differences in organ pathology and cytokine response in Leishmaniasis.Frontiers in immunology · 2025Article
- Recent advances in the genetic engineering of theIranian journal of basic medical sciences · 2025Review
- MicroRNA-194 regulates parasitic load and IL-1β-dependent nitric oxide production in the peripheral blood mononuclear cells of dogs with leishmaniasis.PLoS neglected tropical diseases · 2024Article
- Within-host bayesian joint modeling of longitudinal and time-to-event data of Leishmania infection.PloS one · 2024Article
- Bayesian multivariate longitudinal model for immune responses to Leishmania: A tick-borne co-infection study.Statistics in medicine · 2023Article
- Centrin-deficient Leishmania mexicana confers protection against New World cutaneous leishmaniasis.NPJ vaccines · 2022Article
- A Historic Review of the Role of CD4+ T-Cell Subsets in Development of the Immune Responses against Cutaneous and Visceral LeishmaniasesIranian biomedical journal · 2022Review
- Mechanobiology of immune cells: Messengers, receivers and followers in leishmaniasis aiding synthetic devices.Current research in immunology · 2022Review
- Therapeutic Potential of Photosynthetic Microorganisms for Visceral Leishmaniasis: An Immunological Analysis.Frontiers in immunology · 2022Article
- Host SUMOylation Pathway Negatively Regulates Protective Immune Responses and PromotesFrontiers in cellular and infection microbiology · 2022Article
- Humoral response in Leishmaniasis.Frontiers in cellular and infection microbiology · 2022Review
- Antileishmanial Drug Discovery and Development: Time to Reset the Model?Microorganisms · 2021Review
- Pleiotropic Effect of Hormone Insulin-Like Growth Factor-I in Immune Response and Pathogenesis in Leishmaniases.Journal of immunology research · 2021Review
- Role of Cytokines in Experimental and Human Visceral Leishmaniasis.Frontiers in cellular and infection microbiology · 2021Review
- Review
- Role of Host and Parasite MIF Cytokines duringTropical medicine and infectious disease · 2020Review
- A new multi-epitope peptide vaccine induces immune responses and protection against Leishmania infantum in BALB/c mice.Medical microbiology and immunology · 2020Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmania parasites have been widely used in experimental models to understand generation, maintenance and failure of immune responses underlying resistance and susceptibility to infection. The clinical outcomes of Leishmania infection depend on the infecting species and the immune status of the host. Noticeably most people exposed Leishmania never develop overt disease. Understanding the immunological events that result in failure or successful control of the parasites is fundamental to both design and evaluation of vaccines and therapies against the leishmaniases. Recent studies visualizing immune response to Leishmania major in the skin have given new insights into the different immune cells acting as hosts the parasite during different stage of infection. Control of Leishmania infection and disease progression has been associated with generation of T-helper (Th) 1 and Th2 responses respectively. Though still valid in several aspects, the Th1/Th2 paradigm is an oversimplification in need of revision. Th2 polarization has never explained severity of human leishmanial disease and a number of other T-cell subsets, including regulatory T- and Th17- cells, have important roles in susceptibility and resistance of both experimental and human leishmanial disease. This review gives an updated overview of immunological response considered to be of importance in protection, susceptibility, disease progression and cure of leishmaniasis, with a special emphasis on human diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.